Clinical trials: multiple sclerosis
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Multiple Sclerosis, Relapsing-Remitting
Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells
Open-label, single center, phase I clinical trial to assess the safety, tolerability and preliminary efficacy and in vivo mechanisms of action of i.v.
- Trial name
- ETIMS (NCT01414634)
- Testing
- ETIMS
- Volunteers
- 9 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis
Oral Cladribine B-cell Study
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
- Trial name
- NCT06415864
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable…
- Trial name
- NCT00475865
- Testing
- Teriflunomide, Glatiramer Acetate (GA)
- Where
- 6 sites in United States, Austria and 4 more
- Volunteers
- 123 people
- Sponsor
- Sanofi
Multiple Sclerosis
Effects of Acthar on Recovery From Cognitive Relapses in MS
The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.
- Trial name
- NCT02290444
- Testing
- Adrenocorticotropic Hormone
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- State University of New York at Buffalo
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo…
- Trial name
- RADIANCE (NCT01628393)
- Testing
- Ozanimod
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 258 people
- Sponsor
- Celgene
Autoimmune Diseases, Relapsing Multiple Sclerosis
Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
The proposed randomized, open label, with treat as usual control group (standard treatment or any disease modifying drugs), crossover phase II study will be conducted in 40 patients (n=20 per group) with the relapsing forms of…
- Trial name
- NCT03183869
- Testing
- Fecal microbiota
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Relapsing Remitting Multiple Sclerosis
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.
- Trial name
- INSPIRE (NCT01767701)
- Testing
- Raltegravir
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis, Clinically Isolated Syndrome
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
This study will evaluate the potential placental transfer of ocrelizumab in pregnant women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of…
- Trial name
- MINORE (NCT04998812)
- Testing
- Ocrelizumab
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT03737851
- Testing
- elezanumab
- Where
- 49 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- AbbVie
TSC1, TSC2
Everolimus for Cancer With TSC1 or TSC2 Mutation
In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.
- Conditions
- TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
- Trial name
- NCT02201212
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Sclerosis
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- ALLEGRO (NCT00509145)
- Testing
- Laquinimod
- Where
- 144 sites in United States, Austria and 22 more
- Volunteers
- 1,106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Osteoporosis, Multiple Sclerosis
Zoledronic Acid in MS-patients With Osteoporosis
This study is designed to evaluate the efficacy and safety of zoledronic acid 5 mg intravenous (i.v.) relative to placebo in Multiple Sclerosis (MS) patients with osteoporosis and to support the optimal use of zoledronic acid for…
- Trial name
- EXALT (NCT01166178)
- Testing
- Zoledronic Acid, Calcium and Vitamin D combination
- Where
- 15 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis
Relapsing-Remitting Multiple Sclerosis
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
- Trial name
- NCT00882999
- Testing
- LY2127399
- Where
- 63 sites in United States, Bulgaria and 11 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis, Relapsing-Remitting
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- CLARITY (NCT00213135)
- Testing
- Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg
- Volunteers
- 1,326 people
- Sponsor
- EMD Serono
Relapsing Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg…
- Trial name
- NCT01185821
- Testing
- BAF312
- Where
- 46 sites in United States, Canada and 10 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Multiple Sclerosis, Overactive Bladder
PTNS for Female Patients Suffering From Multiple Sclerosis
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of Percutaneous Tibial Nerve Stimulation (PTNS) in treating bladder overactivity (OAB) symptoms in multiple sclerosis (MS) patients.
- Trial name
- PTNS-MS (NCT05422625)
- Testing
- PTNS Treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Corewell Health East
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Primary Objective: Assess the antibody response to influenza vaccine in patients with relapsing form of multiple sclerosis (RMS) treated with teriflunomide compared to a reference population.
- Trial name
- TERIVA (NCT01403376)
- Testing
- teriflunomide, Interferon-β-1, Influenza vaccine
- Where
- 14 sites in Austria, Canada and 3 more
- Volunteers
- 128 people
- Sponsor
- Sanofi